19:19 , Aug 10, 2018 |  BC Week In Review  |  Clinical News

FDA approves Kyowa's Poteligeo for CTCL

FDA approved Poteligeo mogamulizumab-kpkc from Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) to treat the two most common forms of cutaneous T cell lymphoma (CTCL). The agency approved Poteligeo to treat adults with relapsed or refractory mycosis...
18:31 , Aug 8, 2018 |  BC Extra  |  Company News

FDA approves Kyowa's Poteligeo for CTCL

FDA approved Poteligeo mogamulizumab-kpkc from Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) to treat the two most common forms of cutaneous T cell lymphoma. The agency approved Poteligeo to treat adults with relapsed or refractory mycosis fungoides...
15:02 , Dec 22, 2017 |  BC Week In Review  |  Financial News

FLX Bio raises $60M series C

Cancer company FLX Bio Inc. (South San Francisco, Calif.) raised $60 million in a series C round from new investor GV (formerly Google Ventures) and existing investors The Column Group, Kleiner Perkins, Topspin Partners and...
13:52 , Dec 21, 2017 |  BC Extra  |  Financial News

FLX Bio raises $60M series C

Cancer company FLX Bio Inc. (South San Francisco, Calif.) raised $60 million in a series C round from new investor GV (formerly Google Ventures) and existing investors The Column Group, Kleiner Perkins, Topspin Partners and...
04:17 , Dec 15, 2017 |  BC Week In Review  |  Clinical News

Kyowa's Poteligeo meets in Phase III for CTCL

Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) said Poteligeo mogamulizumab (AMG 761, KW-0761) met the primary endpoint of improving progression-free survival (PFS) in the Phase III MAVORIC trial to treat mycosis fungoides or Sézary syndrome, which...
20:06 , Dec 10, 2017 |  BC Extra  |  Clinical News

Kyowa's Poteligeo meets in Phase III for CTCL

Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) said Poteligeo mogamulizumab (AMG 761, KW-0761) met the primary endpoint of improving progression-free survival (PFS) in the Phase III MAVORIC trial to treat mycosis fungoides or Sézary syndrome, which...
21:55 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

Kyowa's mogamulizumab gets priority review for CTCL

FDA accepted and granted Priority Review to a BLA from Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) for Poteligeo mogamulizumab (KW-0761, AMG 761) to treat cutaneous T cell lymphoma in patients who have received at least...
18:26 , Nov 28, 2017 |  BC Extra  |  Company News

Kyowa's mogamulizumab gets Priority Review for CTCL

FDA accepted and granted Priority Review to a BLA from Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) for Poteligeo mogamulizumab (AMG 761, KW-0761) to treat cutaneous T cell lymphoma in patients who have received at least...
23:28 , Oct 31, 2017 |  BioCentury  |  Emerging Company Profile

Two faces of myeloid

Pionyr Immunotherapeutics Inc. has a pipeline of preclinical antibodies that could enable it to selectively deplete immunosuppressive myeloid cells from tumors without harming immune-stimulating myeloid cells. Myeloid cells such as tumor-associated macrophages (TAMs) and myeloid-derived...
01:10 , Aug 11, 2017 |  BC Innovations  |  Strategy

The flip-side of immunotherapy

In the smaller print of last week’s deal between IFM Therapeutics Inc. and Bristol-Myers Squibb Co. was the latest example of a growing trend of companies aiming to draw extra value out of a cancer...